abstract：:Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chemotherapy with or wi...

journal_title：Oncoimmunology

authors： Hardy-Werbin M,Rocha P,Arpi O,Taus Á,Nonell L,Durán X,Villanueva X,Joseph-Pietras D,Nolan L,Danson S,Griffiths R,Lopez-Botet M,Rovira A,Albanell J,Ottensmeier C,Arriola E

更新日期：2019-03-27 00:00:00

abstract：:Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a significant correlation b...

journal_title：Oncoimmunology

authors： Pan Y,Fei Q,Xiong P,Yang J,Zhang Z,Lin X,Pan M,Lu F,Huang H

更新日期：2019-03-01 00:00:00

abstract：:In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system's natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon (IFN) α was recentl...

journal_title：Oncoimmunology

authors： Rothschilds A,Tzeng A,Mehta NK,Moynihan KD,Irvine DJ,Wittrup KD

更新日期：2019-02-19 00:00:00

abstract：:We previously showed that the colorectal cancer colonizing bacterium Fusobacterium nucleatum protects tumors from immune cell attack via binding of the fusbacterial Fap2 outer-membrane protein to TIGIT, a checkpoint inhibitory receptor expressed on T cells and NK cells. Helicobacter pylori, the causative agent for pep...

journal_title：Oncoimmunology

authors： Gur C,Maalouf N,Gerhard M,Singer BB,Emgård J,Temper V,Neuman T,Mandelboim O,Bachrach G

更新日期：2019-01-29 00:00:00

abstract：:Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20-40% of patients to generate anti-tumor immune responses. Combination treatment approaches with chemotherapeutic drugs may enable responses in the remaining patient cohorts. In this regard, a handful of ...

journal_title：Oncoimmunology

authors： Bauzon M,Drake PM,Barfield RM,Cornali BM,Rupniewski I,Rabuka D

更新日期：2019-01-22 00:00:00

abstract：:Radiofrequency ablation (RFA) of colorectal liver metastases activates a specific T-cell response that is ineffective in avoiding recurrence. Recently, local immunomodulation garnered interests as a way to improve the immune response. We were interested in improving the RFA immune response priming to propose a curativ...

journal_title：Oncoimmunology

authors： Lemdani K,Mignet N,Boudy V,Seguin J,Oujagir E,Bawa O,Peschaud F,Emile JF,Capron C,Malafosse R

更新日期：2019-01-10 00:00:00

abstract：:Under physiological conditions, PD-1/PD-L1 interactions regulate unwanted over-reactions of immune cells and contribute to maintain peripheral tolerance. However, in tumor microenvironment, this interaction may greatly compromise the immune-mediated anti-tumor activity. PD-1+ NK cells have been detected in high percen...

journal_title：Oncoimmunology

authors： Mariotti FR,Petrini S,Ingegnere T,Tumino N,Besi F,Scordamaglia F,Munari E,Pesce S,Marcenaro E,Moretta A,Vacca P,Moretta L

更新日期：2018-12-25 00:00:00

abstract：:Although the proteasome inhibitor bortezomib has significantly improved the survival of patients with multiple myeloma (MM), the disease remains fatal as most patients eventually develop progressive disease. Recent data indicate that MM cells can evade bortezomib-induced cell death by undergoing autophagy as a consequ...

journal_title：Oncoimmunology

authors： Carlsten M,Namazi A,Reger R,Levy E,Berg M,St Hilaire C,Childs RW

更新日期：2018-11-02 00:00:00

abstract：:Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune respo...

journal_title：Oncoimmunology

authors： Schlößer HA,Thelen M,Lechner A,Wennhold K,Garcia-Marquez MA,Rothschild SI,Staib E,Zander T,Beutner D,Gathof B,Gilles R,Cukuroglu E,Göke J,Shimabukuro-Vornhagen A,Drebber U,Quaas A,Bruns CJ,Hölscher AH,Von Bergwelt-Bai

更新日期：2018-11-02 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

journal_title：Oncoimmunology

authors： Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

更新日期：2018-10-31 00:00:00

abstract：:Regulatory T cells (Tregs) facilitate primary and metastatic tumour growth through the suppression of anti-tumour immunity. Emerging evidence suggests a distinct role for Tregs in mediating tissue repair and barrier integrity in the lungs by IL-33 mediated production of the growth factor amphiregulin (AREG). Dependent...

journal_title：Oncoimmunology

authors： Halvorsen EC,Franks SE,Wadsworth BJ,Harbourne BT,Cederberg RA,Steer CA,Martinez-Gonzalez I,Calder J,Lockwood WW,Bennewith KL

更新日期：2018-10-16 00:00:00

abstract：:Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood. Here, we show that oncolysis of mesothelioma by modified vaccinia Tiantan (MVTT) induces damage-associated molecular patterns exposure. A...

journal_title：Oncoimmunology

authors： Tan Z,Liu L,Chiu MS,Cheung KW,Yan CW,Yu Z,Lee BK,Liu W,Man K,Chen Z

更新日期：2018-10-16 00:00:00

abstract：:Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are bona fide oncogenic drivers of acute myeloid leukemia and glioma because the neomorphic enzymes catalyze the synthesis of R-2-hydroxylutarate (R-2-HG), an oncom...

journal_title：Oncoimmunology

authors： Galluzzi L,Kroemer G

更新日期：2018-10-16 00:00:00

abstract：:Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microenvironment. In this...

journal_title：Oncoimmunology

authors： Hagihara K,Chan S,Zhang L,Oh DY,Wei XX,Simko J,Fong L

更新日期：2018-10-01 00:00:00

abstract：:Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

journal_title：Oncoimmunology

authors： Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

更新日期：2018-09-26 00:00:00

abstract：:Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). In this first line, open-label, single-arm, phase 2 study, pati...

journal_title：Oncoimmunology

authors： Lester JF,Casbard AC,Al-Taei S,Harrop R,Katona L,Attanoos RL,Tabi Z,Griffiths GO

更新日期：2018-09-07 00:00:00

abstract：:MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

journal_title：Oncoimmunology

authors： Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

更新日期：2018-09-06 00:00:00

abstract：:Efforts to reduce immunosuppression in the solid tumor microenvironment by blocking the recruitment or polarization of tumor associated macrophages (TAM), or myeloid derived suppressor cells (MDSCs), have gained momentum in recent years. Expanding our knowledge of the immune cell types, cytokines, or recruitment facto...

journal_title：Oncoimmunology

authors： Moyes KW,Davis A,Hoglund V,Haberthur K,Lieberman NA,Kreuser SA,Deutsch GH,Franco S,Locke D,Carleton MO,Gilbertson DG,Simmons R,Winter C,Silber J,Gonzalez-Cuyar LF,Ellenbogen RG,Crane CA

更新日期：2018-08-27 00:00:00

abstract：:Despite increasing evidence for a protective role of invariant (i) NKT cells in the control of graft-versus-host disease (GVHD), the mechanisms underpinning regulation of the allogeneic immune response in humans are not known. In this study, we evaluated the distinct effects of human in vitro expanded and flow-sorted ...

journal_title：Oncoimmunology

authors： Coman T,Rossignol J,D'Aveni M,Fabiani B,Dussiot M,Rignault R,Babdor J,Bouillé M,Herbelin A,Coté F,Moura IC,Hermine O,Rubio MT

更新日期：2018-08-23 00:00:00

abstract：:We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP-870,893 and the CT...

journal_title：Oncoimmunology

authors： Bajor DL,Mick R,Riese MJ,Huang AC,Sullivan B,Richman LP,Torigian DA,George SM,Stelekati E,Chen F,Melenhorst JJ,Lacey SF,Xu X,Wherry EJ,Gangadhar TC,Amaravadi RK,Schuchter LM,Vonderheide RH

更新日期：2018-08-20 00:00:00

abstract：:Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer immunotherapy in general is the immunosuppressive tumor microenvironment, which hampers the maturation and activation of DCs. The...

journal_title：Oncoimmunology

authors： Zafar S,Sorsa S,Siurala M,Hemminki O,Havunen R,Cervera-Carrascon V,Santos JM,Wang H,Lieber A,De Gruijl T,Kanerva A,Hemminki A

更新日期：2018-08-15 00:00:00

abstract：:Co-stimulatory signals induced by ligands of the tumor necrosis factor superfamily (TNFSF) play a central role in T cell activation and have emerged as a promising strategy in cancer immunotherapy. Here, we established a novel class of bifunctional co-stimulatory fusion proteins with the aim to boost T cell activation...

journal_title：Oncoimmunology

authors： Fellermeier-Kopf S,Gieseke F,Sahin U,Müller D,Pfizenmaier K,Kontermann RE

更新日期：2018-08-01 00:00:00

abstract：:Despite recent therapeutic progress, plasmablastic lymphoma (PBL), a distinct entity of high grade B cell lymphoma, is still an aggressive lymphoma with adverse prognosis. PBL commonly occurs in patients with HIV infection and PBL cells frequently express Epstein Barr virus (EBV) genome with type I latency. Occasional...

journal_title：Oncoimmunology

authors： Gravelle P,Péricart S,Tosolini M,Fabiani B,Coppo P,Amara N,Traverse-Gléhen A,Van Acker N,Brousset P,Fournie JJ,Laurent C

更新日期：2018-07-30 00:00:00

abstract：:Macrophages in the tumor microenvironment respond to complex cytokine signals. How these responses shape the phenotype of tumor-associated macrophages (TAMs) is incompletely understood. Here we explored how cytokines of the tumor milieu, interleukin (IL)-6 and IL-4, interact to influence target gene expression in prim...

journal_title：Oncoimmunology

authors： Gupta S,Jain A,Syed SN,Snodgrass RG,Pflüger-Müller B,Leisegang MS,Weigert A,Brandes RP,Ebersberger I,Brüne B,Namgaladze D

更新日期：2018-07-30 00:00:00

abstract：:Surgical resection of the primary tumor provides the best chance of cure for patients with colorectal carcinoma (CRC). However, bacterial translocation during intestinal surgery has been correlated with poor long-term oncological outcome. Therefore, we investigated the influence of bacterial contamination during colon...

journal_title：Oncoimmunology

authors： Grewal S,Korthouwer R,Bögels M,Braster R,Heemskerk N,Budding AE,Pouw SM,van Horssen J,Ankersmit M,Meijerink J,van den Tol P,Oosterling S,Bonjer J,Gül N,van Egmond M

更新日期：2018-07-26 00:00:00

abstract：:The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small fraction of patients, underlining urgent need for improvement. We pr...

journal_title：Oncoimmunology

authors： Ekiz HA,Lai SA,Gundlapalli H,Haroun F,Williams MA,Welm AL

更新日期：2018-07-11 00:00:00

abstract：:The signal adapter MyD88, an essential component of Toll-like receptor (TLR) signaling, is important for gut-microbiome interactions. However, its contribution to cancer and its cell-type specific functions are controversially discussed. Therefore, we generated new tissue-specific mouse models and analyzed the clinica...

journal_title：Oncoimmunology

authors： Holtorf A,Conrad A,Holzmann B,Janssen KP

更新日期：2018-06-11 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:Despite the opposite roles of Tbet and Foxp3 in the immune system as well as in tumour biology, recent studies have demonstrated the presence of of CD4+ T cells, expressing both, Tbet and Foxp3. Although Tbet+Foxp3+ T cells are currently a subject of intense research, less is known about their biological function espe...

journal_title：Oncoimmunology

authors： Kachler K,Holzinger C,Trufa DI,Sirbu H,Finotto S

更新日期：2018-04-25 00:00:00

abstract：:We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-es...

journal_title：Oncoimmunology

authors： Kebenko M,Goebeler ME,Wolf M,Hasenburg A,Seggewiss-Bernhardt R,Ritter B,Rautenberg B,Atanackovic D,Kratzer A,Rottman JB,Friedrich M,Vieser E,Elm S,Patzak I,Wessiepe D,Stienen S,Fiedler W

更新日期：2018-04-18 00:00:00

abstract：:A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues. However, different tissues have unique immune components, and very little is known about whether effector T cells induced against tumors in one tissue can wo...

journal_title：Oncoimmunology

authors： O'Konek JJ,Ambrosino E,Bloom AC,Pasquet L,Massilamany C,Xia Z,Terabe M,Berzofsky JA

更新日期：2018-04-09 00:00:00

abstract：:Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lin...

journal_title：Oncoimmunology

authors： Atherton MJ,Stephenson KB,Tzelepis F,Bakhshinyan D,Nikota JK,Son HH,Jirovec A,Lefebvre C,Dvorkin-Gheva A,Ashkar AA,Wan Y,Stojdl DF,Belanger EC,Breau RH,Bell JC,Saad F,Singh SK,Diallo JS,Lichty BD

更新日期：2018-03-27 00:00:00

abstract：:Purpose: Tumor development has been closely linked to tumor microenvironment, particularly in terms of myeloid-derived suppressive cells (MDSCs), a heterogeneous population of immature myeloid cells that protect tumors from elimination by immune cells. Approaches aimed at blocking MDSC accumulation could improve cance...

journal_title：Oncoimmunology

authors： Qin G,Lian J,Huang L,Zhao Q,Liu S,Zhang Z,Chen X,Yue D,Li L,Li F,Wang L,Umansky V,Zhang B,Yang S,Zhang Y

更新日期：2018-03-13 00:00:00

abstract：:Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor response to type-II i...

journal_title：Oncoimmunology

authors： Luo N,Formisano L,Gonzalez-Ericsson PI,Sanchez V,Dean PT,Opalenik SR,Sanders ME,Cook RS,Arteaga CL,Johnson DB,Balko JM

更新日期：2018-03-06 00:00:00

abstract：:Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In order to devise a treatment strategy for patients with glioblastoma...

journal_title：Oncoimmunology

authors： Suryadevara CM,Desai R,Abel ML,Riccione KA,Batich KA,Shen SH,Chongsathidkiet P,Gedeon PC,Elsamadicy AA,Snyder DJ,Herndon JE 2nd,Healy P,Archer GE,Choi BD,Fecci PE,Sampson JH,Sanchez-Perez L

更新日期：2018-02-21 00:00:00

abstract：:Immunogenic cell death (ICD) induced by anticancer chemotherapeutics is usually preceded by premortem stress affecting the endoplasmic reticulum (ER). This ER stress does not reflect a canonical unfolded protein response (UPR) but rather manifests solely at the level of the phosphorylation of eIF2α. eIF2α phosphorylat...

journal_title：Oncoimmunology

authors： Bezu L,Sauvat A,Humeau J,Leduc M,Kepp O,Kroemer G

更新日期：2018-02-14 00:00:00

abstract：:Lung-specific overexpression of prostacyclin synthase (PGIS) decreases tumor initiation in murine lung cancer models. Prostacyclin analogs prevent lung tumor formation in mice and reverse bronchial dysplasia in former smokers. However, the effect of prostacyclin on lung cancer progression has not been well studied. We...

journal_title：Oncoimmunology

authors： Li HY,McSharry M,Walker D,Johnson A,Kwak J,Bullock B,Neuwelt A,Poczobutt JM,Sippel TR,Keith RL,Weiser-Evans MCM,Clambey E,Nemenoff RA

更新日期：2018-02-13 00:00:00

abstract：:CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and o...

journal_title：Oncoimmunology

authors： Roman Aguilera A,Lutzky VP,Mittal D,Li XY,Stannard K,Takeda K,Bernhardt G,Teng MWL,Dougall WC,Smyth MJ

更新日期：2018-02-01 00:00:00

abstract：:Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy...

journal_title：Oncoimmunology

authors： Du S,McCall N,Park K,Guan Q,Fontina P,Ertel A,Zhan T,Dicker AP,Lu B

更新日期：2018-01-29 00:00:00

abstract：:VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation...

journal_title：Oncoimmunology

authors： Schmitz-Winnenthal FH,Hohmann N,Schmidt T,Podola L,Friedrich T,Lubenau H,Springer M,Wieckowski S,Breiner KM,Mikus G,Büchler MW,Keller AV,Koc R,Springfeld C,Knebel P,Bucur M,Grenacher L,Haefeli WE,Beckhove P

更新日期：2018-01-16 00:00:00